comparemela.com

Latest Breaking News On - Durect corporation - Page 3 : comparemela.com

Polycaprolactone Market to Grow at a CAGR of 9 5% during the 2023 to 2031 Forecast Period

Increase in adoption of lightweight and high-performance materials in various end-use industries is also boosting demand for polycaprolactone.Wilmington, Delaware, United States, Nov. 16, 2023 (GLOBE NEWSWIRE) Transparency Market Research Inc. - The global polycaprolactone market stood at US$ 500 million in 2023 and is projected to reach US$ 1.1 billion in 2031. The global polycaprolactone market is anticipated to expand at a CAGR of 9.5% between 2023 and 2031. Polycaprolactone (PCL) is a par

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update

/PRNewswire/ DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the.

HC Wainwright Downgrades Durect to Neutral From Buy

Sector Update: Health Care Stocks Mixed Late Wednesday Afternoon -November 08, 2023 at 03:46 pm EST

Health care stocks were mixed late Wednesday afternoon, with the NYSE Health Care Index little changed and the Health Care Select Sector SPDR Fund down 0.1%. The iShares Biotechnology ETF fell.

These 2 Strong Buy Penny Stocks Have Massive Upside Potential, Says Oppenheimer

Let’s talk about penny stocks. These are equities that trade for less than $5 per share, at the very bottom of the price range. While they are priced that low for a reason – and the reasons may vary – a low price in itself doesn’t mean that the stock’s fundamentals are sour. Smart investors can find some true bargains among penny stocks and set themselves up for outsized gains. The opportunity is linked to a simple question: Why is the company’s stock priced so low? If the answer is mainly benig

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.